PharmaBlock Sciences of Nanjing, a CDMO, has acquired a GMP compliant manufacturing facility in China from Porton Pharma. The facility, a three-year-old, 1.5 million square foot plant located in Shangyu, Zhejiang Province, will provide preclinical-, clinical- and commercial- stage manufacturing of intermediates for PharmaBlock clients. It is PharmaBlock’s second manufacturing plant. At the new site, PharmaBlock plans to build an additional API manufacturing plant, with construction beginning this year. The purchase price was not disclosed.
Source: China Biotoday
